FIELD: biotechnology.
SUBSTANCE: group of inventions relates to versions of recombinant UvsX recombinase, a nucleic acid molecule encoding recombinant UvsX recombinase, method for recombinant polymerase amplification for amplification of a target molecule of nucleic acid using said recombinase, as well as a kit containing it. Disclosed is a recombinant UvsX recombinase comprising an amino acid sequence which is at least 90 %, 95 % or 99 % identical to the sequence SEQ ID NO: 1, where recombinant UvsX recombinase comprises a substitution for a lysine residue in a position functionally equivalent to position 256 in the sequence SEQ ID NO: 1 UvsX RB49. Also recombinant recombinant UvsX containing an amino acid sequence which is at least 90 %, 95 % or 99 % identical SEQ ID NO: 1 sequence, where recombinant UvsX recombinase comprises a lysine residue substitution in a position functionally equivalent to position 256 in the sequence SEQ ID NO: 1 UvsX RB49, and replacing the serine residue in a position functionally equivalent to His63 in the amino acid sequence RB49 UvsX. Also disclosed are a nucleic acid molecule encoding recombinant recombinase UvsX, recombinant polymerase amplification method for amplifying a target molecule of a nucleic acid using said recombinase, as well as a recombinase polymerase reaction kit containing said recombinase.
EFFECT: group of inventions provides improved recombinase-mediated amplification of nucleic acids.
22 cl, 7 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCTION OF ARENAVIRUS, AS WELL AS ARENAVIRUS MUTANTS WITH ANTITUMOR PROPERTIES | 2019 |
|
RU2812046C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| ISOLATED MODIFIED VPI CAPSID PROTEIN OF ADENO-ASSOCIATED VIRUS OF SEROTYPE 9 (AAV9), CAPSID AND VECTOR BASED THEREON | 2021 |
|
RU2825667C2 |
| REDUCED NICOTINE CONVERSION INTO NORNICOTINE IN PLANTS | 2015 |
|
RU2733837C2 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
